Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients

Katherine C. Fuh, James J. Java, John K. Chan, Daniel S. Kapp, Bradley J. Monk, Robert A. Burger, Robert C. Young, David S Alberts, William P. McGuire, Maurie Markman, Jeffrey Bell, Robert F. Ozols, Deborah K. Armstrong, Carol Aghajanian, Michael A. Bookman, Robert S. Mannel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To compare patient/tumor characteristics and outcomes of Asians to Caucasian patients with epithelial ovarian cancer. Methods: Ancillary data were pooled and analyzed from ten prospective randomized front-line Gynecologic Oncology Group clinical trials from 1996 to 2011. Demographic, clinicopathologic features, disease-specific and all-cause survival were analyzed. Results: Of 7914 patients, 7641 were Caucasian and 273 Asian. When compared to Caucasians, Asians were younger at trial enrollment, had a better performance status, earlier-stage cancers (17.2% vs. 8.1% with stage I; p < 0.001), and were more likely to be of clear cell (15.8% vs. 6.2%, p < 0.001) and mucinous (3.3% vs. 1.9%, p < 0.001) histology. Asians had an improved 5-year disease-specific survival of 54.1% compared to 46.1% for Caucasians, p = 0.001. In multivariate analysis, the Asian race remained a significant prognostic factor for all-cause survival (HR: 0.84; 95% CI: 0.72–0.99; p = 0.04). Other factors predictive of improved survival included younger age, better performance status, optimal cytoreduction, earlier stage, non-clear cell histology, and lower grade tumors. Conclusion: Asians enrolled into phase III ovarian cancer clinical trials were younger, with better performance status, earlier-stage of disease, and have a greater number of clear cell and mucinous tumors. After adjusting for these prognostic factors, Asians have a better survival compared to Caucasians.

Original languageEnglish (US)
JournalGynecologic oncology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Ovarian Neoplasms
Survival
Neoplasms
Histology
Clinical Trials
Multivariate Analysis
Cell Count
Demography

Keywords

  • Bevacizumab
  • Body mass index
  • Clear cell
  • Pharmacogenomics
  • Racial differences
  • Survival outcomes

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer : An NRG Oncology/GOG Ancillary study of 7914 patients. / Fuh, Katherine C.; Java, James J.; Chan, John K.; Kapp, Daniel S.; Monk, Bradley J.; Burger, Robert A.; Young, Robert C.; Alberts, David S; McGuire, William P.; Markman, Maurie; Bell, Jeffrey; Ozols, Robert F.; Armstrong, Deborah K.; Aghajanian, Carol; Bookman, Michael A.; Mannel, Robert S.

In: Gynecologic oncology, 01.01.2019.

Research output: Contribution to journalArticle

Fuh, KC, Java, JJ, Chan, JK, Kapp, DS, Monk, BJ, Burger, RA, Young, RC, Alberts, DS, McGuire, WP, Markman, M, Bell, J, Ozols, RF, Armstrong, DK, Aghajanian, C, Bookman, MA & Mannel, RS 2019, 'Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients', Gynecologic oncology. https://doi.org/10.1016/j.ygyno.2019.05.013
Fuh, Katherine C. ; Java, James J. ; Chan, John K. ; Kapp, Daniel S. ; Monk, Bradley J. ; Burger, Robert A. ; Young, Robert C. ; Alberts, David S ; McGuire, William P. ; Markman, Maurie ; Bell, Jeffrey ; Ozols, Robert F. ; Armstrong, Deborah K. ; Aghajanian, Carol ; Bookman, Michael A. ; Mannel, Robert S. / Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer : An NRG Oncology/GOG Ancillary study of 7914 patients. In: Gynecologic oncology. 2019.
@article{7a39818574ea40e8866f97d05d83ceb6,
title = "Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients",
abstract = "Purpose: To compare patient/tumor characteristics and outcomes of Asians to Caucasian patients with epithelial ovarian cancer. Methods: Ancillary data were pooled and analyzed from ten prospective randomized front-line Gynecologic Oncology Group clinical trials from 1996 to 2011. Demographic, clinicopathologic features, disease-specific and all-cause survival were analyzed. Results: Of 7914 patients, 7641 were Caucasian and 273 Asian. When compared to Caucasians, Asians were younger at trial enrollment, had a better performance status, earlier-stage cancers (17.2{\%} vs. 8.1{\%} with stage I; p < 0.001), and were more likely to be of clear cell (15.8{\%} vs. 6.2{\%}, p < 0.001) and mucinous (3.3{\%} vs. 1.9{\%}, p < 0.001) histology. Asians had an improved 5-year disease-specific survival of 54.1{\%} compared to 46.1{\%} for Caucasians, p = 0.001. In multivariate analysis, the Asian race remained a significant prognostic factor for all-cause survival (HR: 0.84; 95{\%} CI: 0.72–0.99; p = 0.04). Other factors predictive of improved survival included younger age, better performance status, optimal cytoreduction, earlier stage, non-clear cell histology, and lower grade tumors. Conclusion: Asians enrolled into phase III ovarian cancer clinical trials were younger, with better performance status, earlier-stage of disease, and have a greater number of clear cell and mucinous tumors. After adjusting for these prognostic factors, Asians have a better survival compared to Caucasians.",
keywords = "Bevacizumab, Body mass index, Clear cell, Pharmacogenomics, Racial differences, Survival outcomes",
author = "Fuh, {Katherine C.} and Java, {James J.} and Chan, {John K.} and Kapp, {Daniel S.} and Monk, {Bradley J.} and Burger, {Robert A.} and Young, {Robert C.} and Alberts, {David S} and McGuire, {William P.} and Maurie Markman and Jeffrey Bell and Ozols, {Robert F.} and Armstrong, {Deborah K.} and Carol Aghajanian and Bookman, {Michael A.} and Mannel, {Robert S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2019.05.013",
language = "English (US)",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer

T2 - An NRG Oncology/GOG Ancillary study of 7914 patients

AU - Fuh, Katherine C.

AU - Java, James J.

AU - Chan, John K.

AU - Kapp, Daniel S.

AU - Monk, Bradley J.

AU - Burger, Robert A.

AU - Young, Robert C.

AU - Alberts, David S

AU - McGuire, William P.

AU - Markman, Maurie

AU - Bell, Jeffrey

AU - Ozols, Robert F.

AU - Armstrong, Deborah K.

AU - Aghajanian, Carol

AU - Bookman, Michael A.

AU - Mannel, Robert S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To compare patient/tumor characteristics and outcomes of Asians to Caucasian patients with epithelial ovarian cancer. Methods: Ancillary data were pooled and analyzed from ten prospective randomized front-line Gynecologic Oncology Group clinical trials from 1996 to 2011. Demographic, clinicopathologic features, disease-specific and all-cause survival were analyzed. Results: Of 7914 patients, 7641 were Caucasian and 273 Asian. When compared to Caucasians, Asians were younger at trial enrollment, had a better performance status, earlier-stage cancers (17.2% vs. 8.1% with stage I; p < 0.001), and were more likely to be of clear cell (15.8% vs. 6.2%, p < 0.001) and mucinous (3.3% vs. 1.9%, p < 0.001) histology. Asians had an improved 5-year disease-specific survival of 54.1% compared to 46.1% for Caucasians, p = 0.001. In multivariate analysis, the Asian race remained a significant prognostic factor for all-cause survival (HR: 0.84; 95% CI: 0.72–0.99; p = 0.04). Other factors predictive of improved survival included younger age, better performance status, optimal cytoreduction, earlier stage, non-clear cell histology, and lower grade tumors. Conclusion: Asians enrolled into phase III ovarian cancer clinical trials were younger, with better performance status, earlier-stage of disease, and have a greater number of clear cell and mucinous tumors. After adjusting for these prognostic factors, Asians have a better survival compared to Caucasians.

AB - Purpose: To compare patient/tumor characteristics and outcomes of Asians to Caucasian patients with epithelial ovarian cancer. Methods: Ancillary data were pooled and analyzed from ten prospective randomized front-line Gynecologic Oncology Group clinical trials from 1996 to 2011. Demographic, clinicopathologic features, disease-specific and all-cause survival were analyzed. Results: Of 7914 patients, 7641 were Caucasian and 273 Asian. When compared to Caucasians, Asians were younger at trial enrollment, had a better performance status, earlier-stage cancers (17.2% vs. 8.1% with stage I; p < 0.001), and were more likely to be of clear cell (15.8% vs. 6.2%, p < 0.001) and mucinous (3.3% vs. 1.9%, p < 0.001) histology. Asians had an improved 5-year disease-specific survival of 54.1% compared to 46.1% for Caucasians, p = 0.001. In multivariate analysis, the Asian race remained a significant prognostic factor for all-cause survival (HR: 0.84; 95% CI: 0.72–0.99; p = 0.04). Other factors predictive of improved survival included younger age, better performance status, optimal cytoreduction, earlier stage, non-clear cell histology, and lower grade tumors. Conclusion: Asians enrolled into phase III ovarian cancer clinical trials were younger, with better performance status, earlier-stage of disease, and have a greater number of clear cell and mucinous tumors. After adjusting for these prognostic factors, Asians have a better survival compared to Caucasians.

KW - Bevacizumab

KW - Body mass index

KW - Clear cell

KW - Pharmacogenomics

KW - Racial differences

KW - Survival outcomes

UR - http://www.scopus.com/inward/record.url?scp=85067357296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067357296&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2019.05.013

DO - 10.1016/j.ygyno.2019.05.013

M3 - Article

AN - SCOPUS:85067357296

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -